'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Dr Reddys Laboratories has increased 9.83% to Rs 8828.3 crore. Sales of Pharmaceutical Services segment has gone up 7.94% to Rs 1,207.90 crore (accounting for 13.36% of total sales). Sales of Global Generics segment has gone up 9.21% to Rs 7,823.50 crore (accounting for 86.53% of total sales). Sales of Others segment has gone down 42.46% to Rs 10.30 crore (accounting for 0.11% of total sales). Inter-segment sales came down from Rs 262.30 crore to Rs 213.40 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 0.77% to Rs 4,814.20 crore. PBIT of Pharmaceutical Services segment fell 32.33% to Rs 170.60 crore (accounting for 3.54% of total PBIT). PBIT of Global Generics segment rose 2.81% to Rs 4,643.10 crore (a...
Pleaselogin & subscribe to view the full report.
More Reports
|
|